Stock 000756 SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Shandong Xinhua Pharmaceutical Company Limited Share Price Shenzhen S.E.

Equities

000756

CNE000000BG1

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
16.15 CNY +0.94% Intraday chart for Shandong Xinhua Pharmaceutical Company Limited +5.14% -20.76%
25/04 Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/04 Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT

Financials

Sales 2022 7.5B 1.04B 86.5B Sales 2023 8.1B 1.12B 93.39B Capitalization 10.81B 1.49B 125B
Net income 2022 411M 56.77M 4.74B Net income 2023 497M 68.65M 5.73B EV / Sales 2022 2.12 x
Net Debt 2022 225M 31.09M 2.6B Net Debt 2023 440M 60.83M 5.08B EV / Sales 2023 1.39 x
P/E ratio 2022
11.8 x
P/E ratio 2023
7.3 x
Employees 7,104
Yield 2022
2.78%
Yield 2023
4.76%
Free-Float 60.55%
More Fundamentals * Assessed data

Chart Shandong Xinhua Pharmaceutical Company Limited

Dynamic Chart

Latest news about Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Xinhua Pharma Unit's Cefaclor Capsules Passes Regulatory Evaluation MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Supplementary Drug Application CI
Shandong Xinhua Pharmaceutical Posts Higher 2023 Profit MT
Shandong Xinhua Pharmaceutical Proposes New Auditor MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Xinhua Pharma's Ibuprofen Gets Registration Approval in China MT
Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient CI
Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate CI
Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes CI
Shandong Xinhua Pharmaceutical Gets Certificate for Registration of Levamlodiping Besylate Tablets MT
Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg) CI
Respiratory Drug by Xinhua Pharmaceutical Unit Passes Regulatory Evaluation for Generic Drugs in China MT
Xinhua Pharmaceutical's Nine-Month Profit Jumps 34% MT
Shandong Xinhua Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
More news

Press releases Shandong Xinhua Pharmaceutical Company Limited

Shandong Xinhua Pharmaceutical : Announcement In Relation To Delay In Despatch Of Circular PU
Shandong Xinhua Pharmaceutical : Appointment of Independent Financial Adviser PU
Shandong Xinhua Pharmaceutical : Overseas Regulatory Announcement PU
Shandong Xinhua Pharmaceutical : (1)Proposed Non-public Issuance of New a Shares;(2)Connected Transaction;(3)Application for Whitewash Waiver;and (4)Proposed Amendments to Articles of Association PU
Shandong Xinhua Pharmaceutical : Unaudited First Quarter Results of 2021 PU
More press releases

Quotes and Performance

1 day+0.94%
1 week+5.14%
Current month-1.88%
1 month-1.88%
3 months-8.50%
6 months-20.09%
Current year-20.76%
More quotes

Highs and lows

1 week
15.16
Extreme 15.16
16.20
1 month
14.99
Extreme 14.99
17.14
Current year
13.45
Extreme 13.45
20.88
1 year
13.45
Extreme 13.45
26.85
3 years
7.32
Extreme 7.32
48.85
5 years
6.22
Extreme 6.22
48.85
10 years
4.01
Extreme 4.0077
48.85
More quotes

ETFs positioned on Shandong Xinhua Pharmaceutical Company Limited

Name Weight AuM 1st Jan change Investor Rating
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ -0.14% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +1.32% -
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD ETF iMGP RBA Responsible Global Allocation ETF - USD
0.00% 7 M€ +0.11% -
More ETFs positioned on Shandong Xinhua Pharmaceutical Company Limited

Quotes

Date Price Change Volume
30/24/30 16.15 +0.94% 8,523,341
29/24/29 16 +1.91% 8,112,810
26/24/26 15.7 +0.38% 8,168,565
25/24/25 15.64 +1.36% 8,539,651
24/24/24 15.43 +0.19% 5,122,830

End-of-day quote Shenzhen S.E., April 30, 2024

More quotes

Company Profile

SHANDONG XINHUA PHARMACEUTICAL COMPANY LIMITED is a China-based company principally engaged in the development, production and distribution of chemical bulk drugs, preparations and medical intermediates. The Company’s main products include metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, L-dopa, pipemidic acid tablets, compound liquorice tablets and nimodipine tablets. The Company distributes its products in domestic market and to overseas markets, including the Americas, Europe and others.
Sector
Pharmaceuticals
Calendar
23/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 719 Stock
  4. 000756 Stock